|
|
||||||||
1 University of Alabama School of Medicine, Birmingham, AL.
2 Department of Radiology, Brooke Army Medical Center, MCHE-DR, 3851 Roger
Brooke Dr., Fort Sam Houston, TX 78234.
Received May 26, 2005;
accepted after revision August 18, 2005.
This Teaching File article is available for SAM credit and CME
credits when completed with the additional educational material provided in
"Imaging of Pheochromocytoma and Incidental Adrenal Lesions:
Self-Assessment Module." See page
S467 for
details.
Keywords: abdominal imaging cancer CT MRI pheochromocytoma
|
|
|---|
|
|
|---|
|
|
|
|
|
|
|
|---|
|
|
|---|
|
|
|---|
|
|
|---|
By far the most commonly encountered solid adrenal lesion is a benign adrenal adenoma. They are found in approximately 1% of individuals undergoing abdominal CT examinations [1]. These lesions are typically small (< 4 cm) and smoothly marginated with homogeneous attenuation [2]. Visually, they commonly appear similar in density to normal adrenal tissue; however, their high intracellular lipid content typically yields a density similar to that of water (< 10 H) on unenhanced studies. As with attenuation, MRI can take advantage of the typical lipid-rich nature of adenomas; lesions show decreased signal attenuation that results from chemical shift artifacts on out-of-phase imaging.
In patients in whom the adenoma is a lipid-poor variant, the characteristic washout of contrast material during CT may serve as an additional noninvasive means of evaluation. Malignant lesions typically have a washout rate of less than 40% at 15 minutes, whereas adenomas and other benign lesions normally have a washout rate greater than 40% [3] (other authors use a figure of 50% washout [4]). When both attenuation and morphology are considered, the specificity of CT for adrenal adenoma approaches 100% [2].
The myelolipoma, a rare cause of adrenal masses, can be dismissed in this patient. These benign tumors are composed of bone marrow elements and generally contain a large amount of macroscopic fat that is easily recognized on CT or on MRI with fat saturation.
Granulomatous disease is another consideration. Although granulomas can have a varied appearance ranging from a soft-tissue mass to a cystic lesion with associated calcifications, they are most often bilateral and are rarely unilateral [1]. This feature makes the diagnosis of granulomatous disease unlikely in this patient, particularly in the absence of calcifications.
Hemorrhage is a known cause of adrenal lesions. In the absence of trauma, hemorrhage is usually associated with anticoagulation therapy or the presence of an underlying blood dyscrasia [1]. Unilateral adrenal hemorrhage, as in this patient, is most commonly the result of blunt trauma, with the right gland affected more often than the left. On the basis of the appearance, density, enhancing characteristics, and lack of known predisposing factors or a supporting history, hemorrhage should not be a consideration in this patient.
Although uncommonly encountered, ganglioneuromas and neuroblastomas can both be seen in the adrenal gland. Their appearance is nonspecific, seen on CT as soft-tissue masses revealing homogeneous or mildly heterogeneous enhancement. On MRI, ganglioneuromas and neuroblastomas are usually less intense than the liver on T1-weighted sequences and show heterogeneous signal intensity on T2-weighted imaging. Unlike in children, neuroblastomas in adults less commonly contain calcifications. Although the absence of disseminated disease helps exclude a neuroblastoma, ganglioneuromas can have an identical CT and MRI appearance and must be differentiated by other means, such as laboratory analysis or nuclear scintigraphy.
Although rare, one of the most worrisome lesions encountered in the adrenal gland is adenocortical carcinoma. When discovered, they are almost always greater than 6 cm, with a heterogeneous appearance on CT and MRI due to hemorrhage and necrosis. Invasion of the renal vein may be seen [5].
Pheochromocytoma is an uncommon catecholamine-secreting tumor arising from the chromaffin cells of the adrenal medulla. Up to 10% of cases are clinically silent, which, when combined with the increased use of abdominal CT, has led to an increased rate of incidental finding. Varying pathologic degeneration can complicate radiographic evaluation of pheochromocytomas; the presence of necrosis, calcification, fibrosis, cystic degeneration, or intracellular lipid degeneration makes pheochromocytoma difficult to distinguish from other solid adrenal masses. However, a noninvasive method of diagnosis is critical because of the fatal hypertension and arrhythmias that these tumors can precipitate if they are manually disturbed [3].
Pheochromocytoma can be clinically characterized by the rule of 10%: 10% are bilateral, 10% are extraadrenal, 10% are malignant, 10% are hereditary, and 10% are nonfunctioning [3, 6]. The diagnosis is often suspected in the young patient who presents with paroxysmal hypertension and palpitation. Despite this, less than 1% of all hypertension is caused by a pheochromocytoma [3]. Other presenting signs and symptoms include headaches, sweating, and tachycardia, which, when combined with hypertension, have a 91% sensitivity and 94% specificity for the tumor [6].
The workup of a suspected pheochromocytoma should begin with measurement of appropriate biochemical markers, particularly plasma catecholamine levels and 24-hour urine vanillylmandelic acid and metanephrine levels. For those patients in whom the clinical and laboratory suspicion of pheochromocytoma is strong, initial radiologic evaluation is centered on CT [2]. On CT, pheochromocytoma exhibits a wide range of heterogeneity, calcification, and cystic components, so identification is chiefly dependent on attenuation, with most having an unenhanced attenuation greater than 10 H. With contrast administration, a pheochromocytoma rapidly and avidly enhances to greater than 40 H, an indication of the tumor's rich network of capillaries. Once again, contrast-enhanced characterization relies principally on attenuation.
If a mass is not identified on CT, then MRI may prove helpful. Pheochromocytoma usually shows low signal intensity on T1-weighted images and high signal intensity on T2-weighted images. In addition, most pheochromocytomas enhance intensely on MRI with contrast administration. However, T2-weighted intensity is highly variable, leading to as many as 35% of pheochromocytomas being misclassified. Therefore, high signal intensity on T2-weighted images should not be used exclusively to imply or to exclude the diagnosis [3, 5]. In rare instances, pheochromocytomas may contain sufficient intracellular lipid to show signal dropout on opposed phase imaging, mimicking benign adrenal adenomas [3].
In patients in whom neither CT nor MRI is decisive, several radio-nuclide imaging techniques may be beneficial. Iodine-131 MIBG is a structural analogue of norepinephrine, a commonly secreted product of pheochromocytomas. Whole-body imaging performed at 24-72 hours after the administration of MIBG has 80-90% sensitivity and 90-100% specificity for the detection of pheochromocytoma. Indium-111 octreotide, a synthetic octapeptide analogue of somatostatin, is a second radionuclide used in the detection of pheochromocytoma. However, conventional doses of octreotide locate fewer than 30% of tumors. In general, 131I MIBG and 111In octreotide should be considered complementary radionuclides because up to 50% of tumors are visualized only with both agents [2, 3].
Lastly, PET has been used in a few instances to identify pheochromocytoma. The most convincing results have been obtained using 18F-FDG and 18F-fluorodopamine PET. However, PET cannot distinguish between pheochromocytomas and adrenal metastases [3].
|
|
|---|
|
|
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
F. S. Chew and K. P. Banks Imaging of Pheochromocytoma and Incidental Adrenal Lesions: Self-Assessment Module Am. J. Roentgenol., September 1, 2006; 187(3_Supplement): S467 - S469. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |